Position in CELC
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$56,285,560
-$2,496,540 QoQ
Shares Held
538,000
+4.5% QoQ
Ownership
1.10%
of shares outstanding
% of Portfolio
5.64%
of 13F equity value
Holder Rank
#22
of 274 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Apis Capital Advisors, LLC holds $143,156,913 across 11 Biotechnology names. CELC ranks #1 (39.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CELC |
Celcuity Inc.
This page
|
538,000 | $56,285,560 | |
| 2 | ANAB |
Anaptysbio, Inc
|
497,000 | $33,547,500 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
556,000 | $12,154,160 | |
| 4 | ORKA |
Oruka Therapeutics, Inc.
|
112,000 | $10,659,040 | |
| 5 | ABVX |
Abivax S.A.
|
74,000 | $9,861,240 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
112,000 | $6,362,720 | |
| 7 | PVLA |
Palvella Therapeutics, Inc.
|
39,000 | $5,959,980 | |
| 8 | TRAX |
First Tracks Biotherapeutics, Inc.
|
226,000 | $4,547,120 |
All Filings in CELC
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $56,285,560 | 538,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $58,782,100 | 515,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $60,043,480 | 602,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $38,334,400 | 776,000 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||